Updates are available Correction dated 2024-05-16

Article History

Received: 11 July 2023

Accepted: 25 September 2023

First Online: 19 October 2023

Change Date: 16 May 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40744-024-00673-2

Declarations

:

: Hideto Kameda declares consulting fees, speaker fees, honoraria, and/or research grants from AbbVie, Asahi Kasei, BMS, Chugai, Eisai, Eli Lilly and Company, Janssen, Mitsubishi-Tanabe, Novartis, Pfizer, Sanofi, Taisho, and UCB. Kohei Hagimori, Yoji Morisaki, and Ayako Konomi are full-time employees of Eli Lilly Japan K.K and stockholders of Eli Lilly and Company. Thorsten Holzkaemper is a full-time employee of Lilly Deutschland GmbH. Hiroaki Dobashi is a speaker for BMS, Chugai, Eli Lilly and Company, GSK, MSD, Novartis, Pfizer, and UCB Pharma.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committees at all sites where these studies were conducted and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study, and all participants consented to the publication of study results. Protocols and consent forms were approved by the institutional review board or ethics committee of each site, including the Western Institutional Review Board (SPIRIT-P1). A listing of individual sites for SPIRIT-P1 are included in the supplement of the primary manuscript []. SPIRIT-P1 was registered at ClinicalTrials.gov, NCT01695239.